Cardiology

A comparison of the PALISADE and BALANCE trials, with commentary from a leading cardiologist, as the community nears a potential approval in FCS.

The approval to GE Healthcare's cyclotron-produced radioactive diagnostic drug provides another option to adequately identify significant coronary artery disease.

Christie Ballantyne, MD, discusses non-statin therapies, both approved and in development, for managing dyslipidemias from the floor of the 2024 Family Heart Global Summit.

A randomized trial suggests gefarnate significantly reduces triglycerides and LDL-C in older adults on statins with residual hypertriglyceridemia.

The joint guidelines address evidence on the management of patients before, during, and after noncardiac surgery since the last update in 2014.

A Q&A with Nihar Desai, MD, on the PROMPT-Lipid trial and the potential of advancing technology for improving patient care in pragmatic ways.

At the Family Heart Summit, Nihar Desai, MD, discussed using EMR alerts to improve lipid therapy for high-risk ASCVD, as shown in the PROMPT-Lipid trial.

The analysis of LDL-C Management Trends observed disparities in LDL-C goal attainment by race, gender, and age.

EDG-7500 was well-tolerated in healthy patients in Phase 1 while achieving gradient relief without LVEF reductions in the Phase 2 CIRRUS-HCM trial.

A new study revealed those who consume a moderate amount of coffee or caffeine had a 48.1% and 40.7% reduced risk for developing cardiometabolic multimorbidity.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key updates from the European Society of Cardiology (ESC) Congress 2024.

In this edition of the APAC Recap, Erin Pardee, PA-C, discusses the American Society of Preventive Cardiology 2024 Congress on CVD Prevention with Viet Le, DMSc, PA-C.

The agency's designation was granted to plozasiran as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome.

The APAC Recap is a new multimedia series created through a partnership between APAC and HCPLive where members of the Academy of Physician Associates have peer-to-peer discussions centered around recent scientific congresses and meetings.

Lifetime statin treatment increased quality-of-life-adjusted survival in men and women aged ≥70 years with and without previous CVD in the United Kingdom.

Deepak Bhatt, MD, MPH, MBA, discusses the results of a prespecified analysis of the EMPACT-MI trial examining the effect across the spectrum of baseline kidney function.

New study finds ASCVD risk score often misses at-risk patients for first acute coronary syndrome, highlighting need for better prediction methods.

The August 2024 cardiology month in review highlights critical data from the European Society of Cardiology Congress 24 and the latest updates on finerenone.

Deepak Bhatt, MD, MPH, MBA, discusses a group of 4 high-impact studies from ESC Congress 2024: FINEARTS-HF, ABYSS, RESHAPE-HF2, and SHAM-PVI.

Ahmad Masri, MD, MS, highlights a trio of studies from ESC Congress 2024 examining use of aficamten in hypertrophic cardiomyopathy.

Ahmad Masri, MD, MS, discusses the results of a SEQUOIA-HCM substudy leveraging cardiac magnetic resonance to assess structural changes associated with aficamten use in HCM.

Ahmad Masri, MD, MS, discusses an integrated safety analysis of aficamten using data from 3 clinical trials.

Siddharth Patel, MD, MPH, discusses how an AZALEA-TIMI 71 analysis presented at ESC Congress 2024.

EMPACT-MI study shows empagliflozin is safe post-acute MI and reduces heart failure events, with kidney protection across kidney function levels.

ESC 2024: Phase 3 PALISADE trial shows plozasiran significantly lowers triglycerides and pancreatitis risk in FCS; NDA planned by year-end.

Kausik Ray, MD, MPhil, discusses the results of the INTERASPIRE study and how it improves our understanding of the effects of elevated Lp(a).

MAVA-LTE trial data show mavacamten's sustained benefits in symptomatic obstructive HCM, with long-term improvements in LVOT, NT-proBNP, and quality of life.

A meta-analysis shows GLP-1 RAs and SGLT2 inhibitors offer distinct cardiovascular and kidney benefits in type 2 diabetes.

FINEARTS-HF results suggest finerenone may join SGLT2 inhibitors as a second pillar in treating HFmrEF/HFpEF, cutting total heart failure events by 16%.

Asundexian failed to prove noninferiority to apixaban for its primary efficacy outcome in the phase 3 OCEANIC-AF trial.